Anti-inflammatory proteins as therapy targets in chronic rhinosinusitis with hyperplastic nasal polyposis: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-06-29 03:30 GMT | Update On 2021-06-29 03:30 GMT

Researchers have found in a new study that a protein- Deleted in Malignant Brain Tumors-1 (DMBT1) is induced in polyps of chronic rhinosinusitis with nasal polyposis (CRSwNP).

The research has been published in the Glycobiology Journal.

Siglec-8, an immune-inhibitory sialoglycan binding lectin (S8), is expressed on the surface of eosinophils and mast cells, which are potent mediators of allergic inflammation. When S8 engages endogenous sialoglycan ligands, eosinophils undergo apoptosis and mast cell mediator release is inhibited.

In the human airway, Siglec-8 ligands (S8L) are sialylated keratan sulfate chains carried on isoforms of the protein Deleted in Malignant Brain Tumors-1 (DMBT1), an immunoregulatory protein that we recently identified as the endogenous ligand for S8, DMBT1.

Therefore, the authors Hyun Sil Lee and colleagues from the Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, USA conducted the present study to report that S8L is overexpressed in chronic rhinosinusitis with nasal polyposis (CRSwNP), a prevalent eosinophilic laden airway disease.

The study showed the following results-

Quantification and comparison of the degree to which DMBT1 carries the S8L by immunoblot analysis and lectin blot overlay, respectively, from nasal lavage showed that the S8L/DMBT1 ratio was significantly increased in CRSwNP vs. control or CRS patients.
The histological sites of S8L and DMBT1 expression in fresh surgically resected human nasal polyps were identified.

Histochemistry of diseased polyps and adjacent nondiseased middle turbinate (MT) tissue from CRSwNP demonstrated colocalization of S8L and DMBT1 with highest staining in submucosal glands >> epithelium > stoma.
S8L expression was specifically elevated in the submucosal glands and epithelium of polyp tissue compared to MT.

Hence, the authors hypothesized that expression of the isoform of DMBT1 carrying the Siglec-8 binding sialoglycan, DMBT1S8, is induced in polyps of CRSwNP specifically at the site of disease, is produced in the submucosal glands of polyps and secreted into the lumen of the sinonasal cavity as a host response to mitigate eosinophil-mediated inflammation.

Article Source : Glycobiology Journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Anti-inflammatory proteins as therapy targets in chronic rhinosinusitis with hyperplastic nasal polyposis: Study

Similar News

Study finds olfactory impairment to increase the risk of cognitive decline

Thyroid Dysfunction Common After Radiotherapy in Head and Neck Cancer Patients, Study Warns

Innovative imaging tool could improve diagnosis and treatment of hearing loss, states research

Pemivibart Shows Promise as Preventive Treatment for COVID-19, suggests study

Rheumatoid Arthritis May Worsen Chronic Rhinosinusitis and Increase Risk of Postoperative Recurrence: Study Finds

Ampicillin-Sulbactam Outperforms Third-Generation Cephalosporins in Aspiration Pneumonia Outcomes: Study Finds

Adenoid Hypertrophy Linked to Delayed Dental Development but Not Skeletal Growth in Children: Study

Allergic Rhinitis and Nasal Polyps Linked to Chronic Respiratory Diseases: Study